RecruitingObesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
Eligible age
18–65 yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
Sponsor: MBX Biosciences
You may qualify if…
- ✓ Age of \>18 to ≤65 years at the time of signing the informed consent.
- ✓ Has a BMI of ≥30 to \<50 kg/m2 at screening and baseline.
- ✓ Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline.
You may not qualify if…
- ✕ History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.
- ✕ History of currently active pancreatitis, type I and type II diabetes.
- ✕ Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes.
- ✕ A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07142707 · last updated 2026-06-09